Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 in PD-LID
NCT01491932Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of mavoglurant in Parkinson's disease (PD), sponsored by Novartis. Started Mar 2012; status: completed.
02
Drugs
mavoglurant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01491932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01491932.